December 15th, 2015

Alkermes Comments On FDA Panel May Pressure Shares, Says Mizuho

Analyst Vamil Divan believes details in Alkermes' announcement this morning that the FDA will hold an advisory committee meeting on October 9 to discuss ALKS 3831, a treatment of schizophrenia and bipolar disorder, may put pressure on the shares.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.